Study of a Single Dose of Danicopan in Healthy Participants
Study Identifier:
ACH471-001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: Danicopan
- Drug: Placebo
Date
Feb 2016 - Jun 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 21 - 55 Years
Requirements Information
Sex
Female & Male
Age
21 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: Danicopan
- Drug: Placebo
Date
Feb 2016 - Jun 2016
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 21 - 55 Years years
Requirements Information
Protocol Summary
This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan in healthy participants. Four different doses (200 milligrams \[mg\], 600 mg, 1200 mg, 2400 mg) and dose-matched placebo were administered under fasted and fed conditions.
Trial Locations
Location
Status
Location
Clinical Trial Site
Auckland, New Zealand
Status
N/A